| Dean Baker, Center for
Economic and Policy Research |
Promoting
Good Ideas on Drugs: Are Patents the Best Way?
The
Relative Efficiency of Patent and Public Support for Bio-Medical
Research |
| Tim Hubbard, Wellcome Trust Sanger
Institute |
1.
Lessons from the Human Genome Project
2. The need for a treaty to
support research that enters the public domain |
| Warren A. Kaplan, Boston University
Law School |
The
"AntiCommons" Effect: What is the Evidence? |
| Jon Merz, Center for Bioethics, University
of Pennsylvania |
Genetic
Discovery and the Need for Compulsory Licensing |
| Ben Peck, Public Citizen |
Pediatric
Patent Extensions |
| Alan Sager, Boston University School
of Public Health |
Protecting
Consumers Completely and Rewarding Drug Makers Fairly: A prescription
drug peace treaty for the U.S.A. |
| Robert Weissman, Essential Action |
FTAA and
Access to Medicines |
| Rachel M. Cohen, Doctors Without
Borders/MSF |
Access to Essential
Medicines and Intellectual Property Rights in Developing Countries |
| James Love, Consumer
Project on Technology |
1. Restrictions
on exports of medicine: irrational public policy, backdoor efforts
to marginalize compulsory licensing, or Northern protectionism?
2. How to frame a global trade
agreement that promotes R&D, and which is consistent with our
notions of efficiency and fairness |
| Spring Gombe, HAI Europe
/ MSF / Oxfam |
Barriers
to Generics in Central and Eastern Europe
|